Microbiota in Neoadjuvant Chemoimmunotherapy for NSCLC

Locally advanced lung cancer (LALC) has poor prognosis despite multimodal therapies. Neoadjuvant chemoimmunotherapy is now standard for resectable stage II-IIIB NSCLC, but patient responses vary. The gut microbiota, a key immune regulator, has been linked to immunotherapy efficacy, with microbial diversity predicting ICI response and fecal microbiota transplantation improving outcomes. While most studies focus on advanced disease, the microbiota's role in LALC during neoadjuvant therapy remains unclear. Exploring its dynamics may uncover novel biomarkers and strategies to optimize treatment

NCT Number	NCT07752589
Lead Sponsor	Guangdong Provincial People's Hospital Collaborators: Southern Medical University, China
Conditions	Non-Small Cell Carcinoma of Lung, Gut Microbiomes, Neoadjuvant Chemoimmunotherapy
Enrollment	100 participants
Start Date	2026-07-31
Primary Completion	2029-07-31 (estimated)
Study Completion	2029-10-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-07